Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2017
At a glance
- Drugs Dasatinib (Primary) ; Sirolimus (Primary) ; Irinotecan; Temozolomide
- Indications Neuroblastoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 17 Oct 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
- 12 Mar 2013 Planned End Date changed from 1 Nov 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov.